U.S. Markets open in 8 hrs 21 mins
  • S&P Futures

    3,257.25
    +19.25 (+0.59%)
     
  • Dow Futures

    26,874.00
    +159.00 (+0.60%)
     
  • Nasdaq Futures

    10,951.75
    +60.00 (+0.55%)
     
  • Russell 2000 Futures

    1,460.80
    +13.80 (+0.95%)
     
  • Crude Oil

    40.54
    +0.23 (+0.57%)
     
  • Gold

    1,876.30
    -0.60 (-0.03%)
     
  • Silver

    23.35
    +0.16 (+0.69%)
     
  • EUR/USD

    1.1670
    -0.0005 (-0.0467%)
     
  • 10-Yr Bond

    0.6660
    0.0000 (0.00%)
     
  • Vix

    28.51
    -0.07 (-0.24%)
     
  • GBP/USD

    1.2753
    +0.0002 (+0.0128%)
     
  • BTC-USD

    10,691.45
    -69.14 (-0.64%)
     
  • CMC Crypto 200

    217.61
    +8.67 (+4.15%)
     
  • FTSE 100

    5,822.78
    -76.48 (-1.30%)
     
  • Nikkei 225

    23,202.30
    +114.48 (+0.50%)
     

Scott+Scott Attorneys at Law LLP Announces Investigation into Vaxart, Inc. (VXRT)

NEW YORK, Aug. 24, 2020 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, is investigating whether Vaxart, Inc. ("Vaxart" or the "Company") (NASDAQ: VXRT) or certain of its officers, directors, or other affiliates violated federal securities laws.  If you purchased Vaxart common stock in or after June 2020 and have suffered a loss, realized or unrealized, you are encouraged to contact Scott+Scott attorney Rhiana Swartz at (844) 818-6980 for more information.

Vaxart is a small clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform.  In early 2020, Vaxart purportedly began to develop a Covid-19 vaccine.

In late June 2020, Vaxart made a couple of announcements regarding its Covid-19 vaccine and the stock price increased dramatically.

Soon after these announcements, Vaxart's largest shareholder, Armistice Capital, sold massive amounts of its Vaxart shares for a huge profit.

Then, on July 25, 2020, The New York Times published an article entitled Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine.  The article clarified one of Vaxart's announcements and reported that, "Vaxart is not among the companies selected to receive significant financial support from [the U.S. Government's Operation] Warp Speed."

On this news, the price of Vaxart shares dropped and the Company's stock price has continued to decline.

What You Can Do

If you purchased Vaxart common stock, and you wish to discuss this investigation, please contact attorney Rhiana Swartz at (844) 818-6980, or at rswartz@scott-scott.com, or visit the Vaxart investigation page on our website at https://scott-scott.com/investigation/vaxart-inc/.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States.  The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising

CONTACT:

Rhiana Swartz
Scott+Scott Attorneys at Law LLP 
230 Park Ave, 17th Floor, NY, NY 10169
(844) 818-6980
rswartz@scott-scott.com

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/scottscott-attorneys-at-law-llp-announces-investigation-into-vaxart-inc-vxrt-301117268.html

SOURCE Scott+Scott Attorneys at Law LLP